DERMOTIC (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. Approved for diabetic macular edema, melasma. First approved in 1988.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
DERMOTIC is a fluocinolone acetonide corticosteroid available as otic oil/drops, approved in 1988 for topical anti-inflammatory treatment. It is indicated for multiple conditions including diabetic macular edema, melasma, uveitis, retinal vein occlusion, radiation retinopathy, age-related macular degeneration, and acute otitis externa. The drug works by agonizing corticosteroid hormone receptors to reduce inflammation.
Product is in late-stage lifecycle with minimal Part D spending (~$33K in 2023, 1,094 claims), indicating a niche market presence with limited team expansion opportunities.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
Worked on DERMOTIC at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moDERMOTIC offers limited career growth due to approaching loss of exclusivity, minimal commercial spending, and zero linked job postings. Roles available are primarily defensive in nature—focused on market protection, reimbursement optimization, and regulatory compliance rather than expansion or innovation.